Corcept Therapeutics (CORT) Revenue & Revenue Breakdown
Corcept Therapeutics Revenue Highlights
Latest Revenue (Y)
$675.04M
Latest Revenue (Q)
$157.21M
Corcept Therapeutics Revenue by Period
Corcept Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $675.04M | 39.94% |
| 2023-12-31 | $482.38M | 20.04% |
| 2022-12-31 | $401.86M | 9.80% |
| 2021-12-31 | $365.98M | 3.42% |
| 2020-12-31 | $353.87M | 15.46% |
| 2019-12-31 | $306.49M | 21.99% |
| 2018-12-31 | $251.25M | 57.82% |
| 2017-12-31 | $159.20M | 95.77% |
| 2016-12-31 | $81.32M | 61.72% |
| 2015-12-31 | $50.29M | 89.39% |
| 2014-12-31 | $26.55M | 156.36% |
| 2013-12-31 | $10.36M | 213.18% |
| 2012-12-31 | $3.31M | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2010-12-31 | - | -100.00% |
| 2009-12-31 | $29.00K | -86.12% |
| 2008-12-31 | $209.00K | -56.64% |
| 2007-12-31 | $482.00K | 63.95% |
| 2006-12-31 | $294.00K | 100.00% |
| 2005-12-31 | - | 100.00% |
| 2004-12-31 | - | 100.00% |
| 2003-12-31 | - | 100.00% |
| 2002-12-31 | - | 100.00% |
| 2001-12-31 | - | - |
Corcept Therapeutics generated $675.04M in revenue during NA 2024, up 39.94% compared to the previous quarter, and up 220.25% compared to the same period a year ago.
Corcept Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $157.21M | -13.57% |
| 2024-12-31 | $181.89M | -0.36% |
| 2024-09-30 | $182.55M | 11.45% |
| 2024-06-30 | $163.80M | 11.57% |
| 2024-03-31 | $146.81M | 8.42% |
| 2023-12-31 | $135.41M | 9.55% |
| 2023-09-30 | $123.60M | 5.00% |
| 2023-06-30 | $117.72M | 11.42% |
| 2023-03-31 | $105.65M | 2.52% |
| 2022-12-31 | $103.06M | 1.31% |
| 2022-09-30 | $101.73M | -1.60% |
| 2022-06-30 | $103.39M | 10.35% |
| 2022-03-31 | $93.69M | -5.20% |
| 2021-12-31 | $98.82M | 2.80% |
| 2021-09-30 | $96.13M | 4.96% |
| 2021-06-30 | $91.59M | 15.30% |
| 2021-03-31 | $79.44M | -7.35% |
| 2020-12-31 | $85.73M | -0.69% |
| 2020-09-30 | $86.33M | -2.53% |
| 2020-06-30 | $88.56M | -5.02% |
| 2020-03-31 | $93.25M | 6.09% |
| 2019-12-31 | $87.89M | 7.84% |
| 2019-09-30 | $81.50M | 12.80% |
| 2019-06-30 | $72.26M | 11.46% |
| 2019-03-31 | $64.83M | -3.00% |
| 2018-12-31 | $66.83M | 3.70% |
| 2018-09-30 | $64.44M | 3.42% |
| 2018-06-30 | $62.31M | 8.07% |
| 2018-03-31 | $57.66M | 8.22% |
| 2017-12-31 | $53.28M | 24.59% |
| 2017-09-30 | $42.76M | 20.26% |
| 2017-06-30 | $35.56M | 28.84% |
| 2017-03-31 | $27.60M | 15.90% |
| 2016-12-31 | $23.81M | 9.61% |
| 2016-09-30 | $21.73M | 10.15% |
| 2016-06-30 | $19.72M | 22.81% |
| 2016-03-31 | $16.06M | 7.31% |
| 2015-12-31 | $14.97M | 12.86% |
| 2015-09-30 | $13.26M | 10.92% |
| 2015-06-30 | $11.96M | 18.35% |
| 2015-03-31 | $10.10M | 12.07% |
| 2014-12-31 | $9.01M | 23.78% |
| 2014-09-30 | $7.28M | 24.46% |
| 2014-06-30 | $5.85M | 32.83% |
| 2014-03-31 | $4.41M | 7.05% |
| 2013-12-31 | $4.12M | 56.23% |
| 2013-09-30 | $2.63M | 39.29% |
| 2013-06-30 | $1.89M | 10.13% |
| 2013-03-31 | $1.72M | 24.69% |
| 2012-12-31 | $1.38M | 30.52% |
| 2012-09-30 | $1.05M | 20.57% |
| 2012-06-30 | $875.00K | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | -100.00% |
| 2009-06-30 | $6.00K | -75.00% |
| 2009-03-31 | $24.00K | -83.22% |
| 2008-12-31 | $143.00K | 116.67% |
| 2008-09-30 | $66.00K | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | 100.00% |
| 2007-12-31 | - | - |
Corcept Therapeutics generated $157.21M in revenue during Q1 2025, up -13.57% compared to the previous quarter, and up 116.11% compared to the same period a year ago.
Corcept Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HALO | Halozyme Therapeutics | $1.02B | $298.01M |
| CORT | Corcept Therapeutics | $675.04M | $157.21M |
| RARE | Ultragenyx Pharmaceutical | $560.23M | $164.88M |
| INSM | Insmed | $363.71M | $104.44M |
| ANAB | AnaptysBio | $91.28M | $43.11M |
| GLUE | Monte Rosa Therapeutics | $75.62M | $60.65M |
| AGIO | Agios Pharmaceuticals | $36.50M | $8.73M |
| MGTX | MeiraGTx | $33.28M | - |
| CYTK | Cytokinetics | $18.47M | $16.93M |
| NUVB | Nuvation Bio | $7.87M | $5.71M |
| IDYA | IDEAYA Biosciences | $7.00M | $7.00M |
| KROS | Keros Therapeutics | $3.55M | $3.04M |
| EWTX | Edgewise Therapeutics | - | - |
| NXTC | NextCure | - | - |
| DYN | Dyne Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| ERAS | Erasca | - | - |
| SNSE | Sensei Biotherapeutics | - | - |